Virtual Dialogue 2 Videos
Chondrosarcoma CS Foundation, Inc.
Second International Virtual Dialogue
Innovations in Diagnosing and Treating Chondrosarcoma
On Saturday, March 20, 2021; the Chondrosarcoma CS Foundation, Inc. hosted its Second International Virtual Dialogue featuring two prominent world renown experts who introduced new techniques and innovations on how to diagnose and treat Chondrosarcoma. The event was attended by Chondrosarcoma patients, family members and medical oncology specialists from 20 different countries around the world.
Using Medication to Treat Chondrosarcoma
Jonathan C. Trent, M.D. is the Associate Director of Clinical Research and Director of the Bone and Soft-tissue Sarcoma Group, for the Sylvester Comprehensive Cancer Center in Miami, FL. Dr. Trent provided a review of the clinical trials he conducted using Ivosidenib (Tibsovo), a medication used to inhibit the IDH 1 biomarker in Chondrosarcoma. He also talked about the future role medications like Ivosidenib will have in treating Chondrosarcoma.
According to Dr. Trent, they are working on developing a set of medications to inhibit, suppress and irradicate the growth of cancer cells. These medications might even be used to primarily treat Chondrosarcoma as opposed to conducting surgery with wide margins.
Improving the Standard of Care for Chondrosarcoma: Update on Research and Diagnostic Screening Techniques.
Professor Adrienne M Flanagan MB, PhD, is the Head of Academic Pathology at University College London (UCL), and the Clinical Lead for the London Sarcoma Service, and the Royal National Orthopaedic Hospital. She heads the Bone Pathology network for the UK. Professor Flanagan, discussed her research on the molecular classification for primary bone tumours resulting in the introduction of diagnostic markers, for chondrosarcoma, which are now used globally.
She introduced the “liquid biopsy,” an innovative approach to detecting cancer biomarkers from a blood test. A simple blood test can be used to pre-screen, detect and track treatment progress for Chondrosarcoma patients. In the future the “Liquid Biopsy” / Blood Test could replace obtaining tissue samples from surgical biopsies.
Open Discussion: Innovations in Diagnosing and Treating Chondrosarcoma
A candid, open discussion with questions and answers to Dr. Trent and Dr. Flanagan from Chondrosarcoma patients and medical experts. The discussion involved how to get the word out to the Oncology community regarding new medications to treat Chondrosarcoma and innovative means to diagnose and detect Chondrosarcoma. There was a discussion on outreach to parts of the world that do not have the knowledge or means to diagnose or treat Chondrosarcoma. The discussion concluded with talk about the future and how new medications and innovations on the horizon can be used diagnose, treat, track progress as well as monitor results of clinal trials.
If you would like to learn more about CS Foundation or if you would like to learn more about the resources we provide to patients, families, caregivers, and physicians, please contact us by phone or send us a message.
**A Registered 501c3 Non-Profit Charity Organization. All donations are tax-deductible.**